Tumor necrosis factor (TNF) inhibitors have also been associated with reduced AD risk in large epidemiological studies, including a recent retrospective analysis that examined health records of 56 million individuals diagnosed with inflammatory diseases (e.g., rheumatoid arthritis) who were treated with TNF blockers [61, 62]. This evidence concerns the gene TNF and Alzheimer disease.